Skip to content
Sign in
Artwork for Dr. John Campbell
EducationHealth & FitnessMedicine

Dr. John Campbell

Campbellteaching

Hello Everyone, My name is John Campbell and I am a retired Nurse Teacher and former clinical nurse based in England. I also do some teaching in Asia and Africa when time permits. These videos are to help students to learn the background to all forms of health care. My PhD focused on the development of open learning resources for nurses nationally and internationally. LinkedIn profile, https://www.linkedin.com/in/dr-john-campbell-5256223b/ Twitter, https://twitter.com/Johnincarlisle Disclaimer; These media including videos, book, e book, articles, podcasts are not peer-reviewed. They should never replace individual clinical judgement from your own health care provider. No media-based material on this channel is suitable for using as professional medical advice. All comments are also for educational purposed only and must never replace advice from your own health care provider

Play
Open in
  • 772 episodes
  • daily
  • Avg 24 min
  • English

Episodes 772

NewestOldestLongest
All20Unplayed20In progress0Played0
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • October 10 · 18 min

    Natural immunity in Portugal

    Rise of natural acquired immunity Uploaded 01-09-22 Get additional scientific background from John’s free text books, http://159.69.48.3/ (you will need to cut and paste this link into your browser) Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants https://www.nejm.org/doi/full/10.1056/NEJMc2209479?query=TOC&cid=NEJM%20eToc,%20September%201,%202022%20DM1402792_NEJM_Non_Subscriber&bid=1141953912 https://www.nejm.org/doi/suppl/10.1056/NEJMc2209479/suppl_file/nejmc2209479_appendix.pdf Omicron subvariants, BA.1 and BA.2, displaced by BA.5 in many countries Greater transmissibility Partial evasion of BA.1- and BA.2-induced immunity Portugal, one of the first countries affected by a BA.5 predominance N = 9,307,996 All Portuguese residents aged 12 years and older, (National Census 2021) Uninfected people in June 1st 2022 was 5, 328, 287, (57% of the Portuguese population over 12) (PCR tests and rapid antigen tests to diagnose cases) Presence of undocumented infections among the “uninfected” group of individuals 29.2% of infections were not notified (based on the seroprevalence of SARS-CoV-2 anti-N IgG in the population) National coronavirus disease 2019 registry (SINAVE) (all reported cases in the country, regardless of clinical presentation) To calculate the risk of BA.5 infection after documented infection with past variants, including BA.1 and BA.2 Times when different variants represented more than 90% of the isolates To calculate their infection risk during the period of BA.5 dominance Pooled BA.1 and BA.2 (slow transition between the two subvariants) Comparator group Population that did not have any documented infection before BA.5 dominance (June 1, 2022) Results Wuhan-Hu-1 55.7% Alpha 58.8% Delta 64.5% BA.1 / BA.2 7 6.8% We found that previous SARS-CoV-2 infection had a protective effect against BA.5 infection Protection was maximal for previous infection with BA.1 or BA.2 (not suprising) Context Portugal more than 98% of the study population completed the primary vaccination series before 2022 There is a perception that the protection afforded by previous BA.1 or BA.2 infection is very low, given the high number of BA.5 infections among persons with previous BA.1 or BA.2 infection. Our data indicate that this perception is probably a consequence of the larger pool of persons with BA.1 or BA.2 infection than with infection by other subvariants, and it is not supported by the data. Breakthrough infections with the BA.5 subvariant were less likely among persons with a previous SARS-CoV-2 infection history … especially for previous BA.1 or BA.2 infection, than among uninfected persons. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 11 min

    A new dark age

    Professor Angus Dalgleish, physician, oncologist, pathologist, medical researcher and author. Get your copy of The Death of Science, https://gazellebookservices.co.uk/pro... Uploaded 21-02-24 Also by Professor Dalgleish, The Origin of the Virus: The hidden truths behind the microbe that killed millions of people, https://www.amazon.co.uk/dp/185457106... Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 23 min

    Antiviral game changer

    Is this antiviral a game changer, Oral Antiviral, molnupiravir Uploaded 03-10-21 https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/ Merck and Ridgeback Oral Antiviral, molnupiravir (MK-4482, EIDD-2801) Positive Interim Analysis of Phase 3 Study Significantly reduced the risk of hospitalization or death During day 1 to 5 to 29 days Phase 3 MOVe-OUT trial At risk, non-hospitalized adults with mild-to-moderate COVID-19 A global Phase 3, randomized, placebo-controlled, double-blind, multi-site study of non-hospitalized adult patients Brazil, Canada, Chile, Colombia, Egypt, France, Germany, Guatemala, Israel, Italy, Japan, Mexico, Philippines, Poland, Russia, South Africa, Spain, Sweden, Taiwan, Ukraine, the United Kingdom and the United States Eligibility criteria Laboratory-confirmed mild-to-moderate COVID-19 With symptom onset within 5 days of study randomization All patients were required to have at least one risk factor Molnupiravir group Hospitalization or dead, 7.3% of patients 28 out of 385 No deaths Placebo group Hospitalization or dead, 14.1% of patients 53 out of 377 P is 0.0012 8 deaths Data Monitoring Committee in consultation with Food and Drug Administration Recruitment into the study stopped early Due to these positive results Merck, application for Emergency Use Authorization in US Other regulatory bodies worldwide About the Results of the Planned Interim Analysis Evaluated data n = 775 Recruitment 90% of 1,550 the intended sample Molnupiravir reduced the risk of hospitalization and/or death across all key subgroups; Efficacy was not affected by timing of symptom onset or underlying risk factor About 40% of participants had sequencing data Molnupiravir demonstrated consistent efficacy across viral variants Gamma, Delta, and Mu Incidence of adverse event between groups Molnupiravir group Incidence of any adverse event, 35% Drug-related adverse events, 12% Subjects discontinued study therapy due to an adverse event, 1.3% Placebo groups Incidence of any adverse event, 40% Drug-related adverse events, 11% Subjects discontinued study therapy due to an adverse event, 3.4% Merck has said data shows molnupiravir is not capable of inducing genetic changes in human cells, but men enrolled in its trials had to abstain from intercourse or agree to use contraception. Women of child-bearing age in the study could (not) be pregnant and also had to use birth control. https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-covid-19-pill-cuts-risk-death-hospitalization-by-50-study-2021-10-01/ About Merck’s Efforts to Enable Access to Molnupiravir, if it is Granted EUA or Approval Merck has been producing molnupiravir at risk. Merck expects to produce 10 million courses of treatment by the end of 2021 Existing procurement agreement with the U.S. Government Merck will supply approximately 1.7 million courses of molnupiravir to the U.S. government upon EAU $700 per 5 day course (2 doses per day) $1.2 billion purchase agreement for the 1.7 million 5-day treatment courses of molnupiravir MOVe-AHEAD A global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study, evaluating the efficacy and safety of molnupiravir in preventing the spread of COVID-19 within households Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 20 min

    God fashioned therapeutics

    Link to but the book, https://covidthroughoureyes.com.au/products/covid-through-our-eyes-an-australian-story-of-mistakes-mistreatment-and-misinformation Letters from Australia is Alison Bevege's Substack, https://lettersfromaustralia.substack.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 12 min

    Excess deaths in 2023

    ‘Excess mortality’ continuing surge causes concerns Uploaded 27-11-23 https://insurancenewsnet.com/innarticle/excess-mortality-continuing-surge-causes-concerns Life insurance executives and actuaries believe the numbers are alarming Life insurers paid record levels of claims in 2021, biggest one-year increase since 1918 Distributed a record $100.28 billion in total death benefits. Younger adult death rate up 20% in 2023 Center of Disease Control that show mortality rates alarmingly rising for different categories. The surge in excess deaths caught carriers off guard 15 – 19 years % difference from 2019 2018, 1% 2020, 21% 2021, 28% 2022, 21% 2023, (Jan – May), 24% 30 – 34 years % difference from 2019 2018, -1% 2020, 30% 2021, 42% 2022, 30% 2023, (Jan – May), 23% 40 – 44 years % difference from 2019 2018, -2% 2020, 30% 2021, 45% 2022, 30% 2023, (Jan – May), 25% Cause of death data show increased cardiac mortality in all ages. As COVID-related causes declined in 2022, others rose, particularly stroke, diabetes, kidney and liver diseases. Society of Actuaries poll In August 2022, 85% thought excess morality rates would continue to 2025. In September 2023, 79% believed excess mortality rates will continue through 2026. UK data https://app.powerbi.com/view?r=eyJrIjoiYmUwNmFhMjYtNGZhYS00NDk2LWFlMTAtOTg0OGNhNmFiNGM0IiwidCI6ImVlNGUxNDk5LTRhMzUtNGIyZS1hZDQ3LTVmM2NmOWRlODY2NiIsImMiOjh9 Our world in data link https://ourworldindata.org/grapher/excess-mortality-p-scores-average-baseline Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 1 hr 14 min

    How much Vitamin D should one take?

    Consultant Physician, medical researcher and author, Dr David Grimes conducted much original research on the essential to life Vitamin D. Buy his inexpensive latest book here. https://yorkbookshop.com/health-and-personal-development/307-vitamin-d-deficiency-and-covid-19-its-central-role-in-a-world-pandemic.html 2 minor corrections - 150nmol/L = 60ng/mL (not 80ng/mL as stated and at 2min 27secs) 57min 11 secs Calcifidiol appears in the BNF here: https://bnf.nice.org.uk/drugs/calcifediol-monohydrate/ and medicinal form here https://bnf.nice.org.uk/drugs/calcifediol-monohydrate/medicinal-forms/ Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 36 min

    Conspiracy theories

    We Were Badly Misled About the Event That Changed Our Lives Uploaded 07-04-25 https://www.nytimes.com/2025/03/16/opinion/covid-pandemic-lab-leak.html Since scientists began playing around with dangerous pathogens in laboratories, the world has experienced four or five pandemics 1977 Russian flu Almost certainly a research mishap. https://armscontrolcenter.org/wp-content/uploads/2016/02/Escaped-Viruses-final-2-17-14-copy.pdf Scientists quickly suspected the odd 1997 Russian virus 2020, speculation about a laboratory accident - kooks and cranks. Mad / eccentric / pick fights to feel superior / fantastic / insane Many, public health officials, prominent scientists - conspiracy theory A nonprofit, EcoHealth Alliance Lost a grant, planning risky research into bat viruses at Wuhan Institute of Virology, lax safety standards But 77 Nobel laureates and 31 scientific societies lined up to defend EcoHealth Alliance Consensus. We have since learned, however, that to promote the appearance of consensus, some officials and scientists hid or understated crucial facts, misled at least one reporter, orchestrated campaigns of supposedly independent voices, and even compared notes about how to hide their communications in order to keep the public from hearing the whole story. https://www.telegraph.co.uk/us/news/2024/03/26/new-york-times-donald-mcneil-wuhan-lab-leak-theory/ Mr Donald McNeil Jr said their efforts to throw him “off track” influenced the newspaper’s coverage of the theory and likely contributed to the topic being “dropped” for a year. Wuhan laboratory’s research, details now emerged - safety precautions might have been terrifyingly lax. Is this just history? If anyone needs convincing that the next pandemic is only an accident away, check out, Cell https://www.sciencedirect.com/science/article/abs/pii/S0092867425001448 Researchers, (past and present) Wuhan Institute of Virology workers, describe taking samples of viruses found in bats, and experimenting to see if they could infect human cells, and pose a pandemic risk. “insufficient for work with potentially dangerous respiratory viruses.” You’d think that by now we’d have learned it’s not a good idea to test possible gas leaks by lighting a match. And you’d hope that prestigious scientific journals would have learned not to reward such risky research. Why haven’t we learned our lesson? Admitting its risky now – must have always been risky? And that perhaps we were misled on purpose. When Wuhan experienced an outbreak of a novel coronavirus related to ones found in bats, and researchers soon noticed the pathogen had the same rare genetic feature that the EcoHealth Alliance and the Wuhan researchers had proposed inserting into bat coronaviruses, https://theintercept.com/2021/09/23/coronavirus-research-grant-darpa/ you would think EcoHealth would sound the alarm far and wide. It did not. Were it not for public records requests, leaks and subpoenas, the world might never have learned about the troubling similarities between what could easily have been going on inside the lab and what was spreading through the city. https://www.lemonde.fr/en/les-decodeurs/article/2025/02/18/covid-19-how-a-group-of-amateur-investigators-pushed-the-lab-leak-theory_6738298_8.html https://www.nytimes.com/interactive/2024/06/03/opinion/covid-lab-leak.html The proximal origin of SARS-CoV-2 (Nature Medicine, 2020) https://www.nature.com/articles/s41591-020-0820-9 ‘we do not believe that any type of laboratory-based scenario is plausible’ But we later learned through congressional subpoenas of their Slack conversations that while the scientists publicly said the scenario was implausible, privately many of its authors considered the scenario to be not just plausible but likely. https://www.thetimes.com/uk/science/article/how-private-slack-messages-have Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 23 min

    Italy, September 2019

    Covid antibodies found in stored blood samples Uploaded 04-11-22 Milan Institute for Tumour Diseases, Coronavirus antibodies, September, 2019 Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy (October 2021) https://pubmed.ncbi.nlm.nih.gov/33176598/ Full text version https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529295/ Screening and Multiple Intervention on Lung Epidemics (SMILE https://clinicaltrials.gov/ct2/show/NCT03654105 There are no robust data, coronavirus 2 (SARS-CoV-2) infection and spread, prepandemic period worldwide We investigated the presence of SARS-CoV-2 receptor-binding domain (RBD)-specific antibodies Blood samples of 959 asymptomatic individuals, enrolled in a prospective lung cancer screening trial, between September 2019 and March 2020 Plasma samples repository Results SARS-CoV-2 RBD-specific antibodies were detected in, 111 of 959 (11.6%) individuals All the patients were asymptomatic at the time of blood sample collection. Actual timeframe First positive test, 3rd September September 2019 23/162 (14.2%) October 2019 27/166 (16.3%) Second week of February 2020, (more than 30%) By the end of September, Lombardy, Veneto, Piedmont, Emilia Romagna, Liguria, Lazio, Campania, Friuli. Official timeframe End of December 2019, coronavirus 2 identified in Wuhan, Hubei Province, China January 30th 2020 Italy’s first two cases, (two tourists from China tested positive in Rome) February 20, 2020 Lombardy, 38-year-old man, no history of travel Authors This study shows an unexpected very early circulation of SARS-CoV-2 among asymptomatic individuals Several months before the first patient was identified Finding SARS-CoV-2 antibodies in asymptomatic people before the COVID-19 outbreak in Italy may reshape the history of pandemic. Phenomena 1 Underestimation of prevalence Swabs and serology, focused on symptomatic cases Therefore, an underestimation of overall COVID-19 infections (Selection bias) Therefore overestimation of mortality rate May 25 and July 15 (2020) SARS-CoV-2 seroprevalence study, n = 64,660 Prevalence rate was 2.5% Approximately 1.5 million, (many of whom were asymptomatic) Estimate almost 5 times higher than official reports Phenomena 2 Onset of the epidemic, likely to have preceded identification of the first case November–December 2019 Doctors reporting, severe respiratory symptoms in elderly and frail, with atypical bilateral bronchitis, which was attributed to aggressive forms of seasonal influenza Based on these findings, a prior unnoticed circulation of the virus among the Italian population could be hypothesized. October 2019 to February 2020 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428442/ Molecular analysis, PCR, 40 wastewater samples Milan/Lombardy, Turin/Piedmont, and Bologna/Emilia Romagna) Presence of viral RNA, December 18th in Milan and Turin So, in which direction did the virus travel? 7th Military World Games 第七届世界军人运动会 Commonly known as Wuhan 2019 October 18–27, 2019 Around 230,000 volunteers 9,308 athletes from 109 countries competing in 329 events Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 20 min

    Antibodies in 99.3% of youth

    Nearly all youth in England had COVID-19 antibodies by March 2022. Implications for vaccine policies? Uploaded 28-06-22 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights 27 June 2022 Results from Round 3 (3rd March to 25th March 2022) Schools Infection Survey Antibodies in secondary school pupils N = 884 99.3% of had SARS-CoV-2 antibodies, comprised of 64.9% who were vaccinated, and 34.4% who were unvaccinated. Antibodies in primary school pupils N = 884 82.0% had SARS-CoV-2 antibodies, comprised of 0.4% who were vaccinated, and 81.6% who were unvaccinated. Schools Infection Survey https://www.ons.gov.uk/releases/covid19schoolsinfectionsurveyenglandpupilantibodydatamarch2022 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/covid19schoolsinfectionsurvey2021to2022methodsandfurtherinformation The pupil antibody test used in Oral fluid collection Lower sensitivity than blood antibody tests, (estimated at 80.0%) for unvaccinated pupils. Immunoglobulins in oral fluids are at least 1 per 1,000th of blood Pupils were tested for Anti-N (antibodies from natural infection), and anti-S (antibodies from natural infection or vaccination) Comparisons between Round 1, Round 2 and Round 3 Round 1 (10th November to 10th December) Primary, 40.1% Secondary, 82.4% Round 2 (10th January to 3rd February) Primary, 62.4% Secondary, 96.6% Round 3, (3rd March to 25th March 2022) Primary, 82% Secondary, 99.3% Antibody testing in Round 3 Coronavirus cases in England were increasing Omicron BA.1 variant times UK infections https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights Week ending 18 June 2022 Likely caused by Omicron variants BA.4 and BA.5. 1,360,600 (1 in 40 people) in England 68,500 (1 in 45 people) in Wales 59,900 (1 in 30 people) in Northern Ireland 250,700 (1 in 20 people) in Scotland Deaths Coronavirus, 6th sixth leading cause of death in England and Wales 3.3% of deaths in both countries In April 2022, COVID-19 was the third leading cause of death. Causes of death, UK https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/monthlymortalityanalysisenglandandwales/february2022 Dementia and Alzheimer’s Ischaemic heart disease Cerebrovascular disease Chronic lower respiratory disease Cancer, trachea, bronchus, lung Influenza and pneumonia Ill-defined conditions Cancer, colorectal Cancer, lymphoid, haemopoietic Deaths in the US https://www.healthline.com/health/leading-causes-of-death Heart disease, 23.1% Cancer, 21.7% Accidents, (unintentional) 5.9% Chronic lower respiratory diseases, 5.6% Stroke, 5.18% Alzheimer’s 4.23% Diabetes, 2.9% Influenza and pneumonia, 1.88% Kidney disease, 1.8% Suicide, 1.64% Septicemia, 1.42% Chronic liver disease and cirrhosis, 1.39% Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 22 min

    Vaccine effectiveness and longevity in UK

    Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK Uploaded 19-08-21 https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey/results/new-studies https://www.ndm.ox.ac.uk/files/coronavirus/covid-19-infection-survey/finalfinalcombinedve20210816.pdf N = 384,543 Households, 221,909 Obtaining two vaccine doses remains the most effective way to ensure protection against Delta With Delta, Pfizer-BioNTech and Oxford-AstraZeneca vaccines still offer good protection against new infections but effectiveness is reduced compared with Alpha However, Delta infections after two vaccine doses had similar peak levels of virus to those in unvaccinated people (with the Alpha variant, peak virus levels in those infected post-vaccination were much lower) Two doses of either vaccine still provided at least the same level of protection as having had COVID-19 through natural infection People who had been vaccinated after already being infected with COVID-19 had even more protection than vaccinated individuals who had not had COVID-19 before Two doses of Pfizer-BioNTech have greater initial effectiveness against new COVID-19 infections but this declines faster compared with two doses of Oxford-AstraZeneca After four to five months, effectiveness of these two vaccines similar however, long-term effects need to be studied The time between doses does not affect effectiveness in preventing new infections Younger people have even more protection from vaccination than older people UK, third shots https://www.bbc.co.uk/news/live/uk-58266043 Prof Peter Openshaw New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG We can't just look at the antibody levels and think that that equates to levels of protection It still seems that you get a lot of protection from these vaccines, even if the antibody levels have drifted down to some sort of stable level Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 6 min

    Decisions, overwhelmingly wrong

    Direct link to parliament TV, https://parliamentlive.tv/Event/Index/5e1f14d2-72b3-488f-a53c-fc94fee92dac Uploaded 27-01-24 Link to Hansard full transcript, https://hansard.parliament.uk/Commons/2024-01-16/debates/152B485D-812D-43CC-9D25-C2B651564810/ExcessDeathTrends?highlight=westminster%20hall#contribution-46059AFE-9A03-472B-9364-0BF972E2E7D8 Miriam Cates (Penistone and Stocksbridge) (Con) I will be brief, because it is clear that there is far more demand to speak in the debate than there is time. That shows that we absolutely need a longer debate; we need a debate on the Floor of the House, because it is not just Members present who want to speak, and members of the public have shown enormous interest. I will not go over the excellent points that have been made and the data that has been shared. We know we have a problem in this country with excess deaths, particularly among younger people and particularly from cardiovascular disease. That, in itself, is a huge challenge. We need medical experts and statisticians to address those issues—I am not qualified to do so. What I will say is this: lockdown changed everything. Our response to covid changed everything. Just as we look back on different periods of history—before the war; before the industrial revolution—I believe we will look back at before and after lockdown. Lockdown has changed our economy and how we relate to each other. It has changed our health and our understanding of children’s development. The conditions under which those decisions were made—decisions that were overwhelmingly wrong, in my opinion, although I do not blame any individuals, given the pressure they were under—have not changed. The conditions under which we suspended the precautionary principle, ignored the fact that interventions may cause harm, suspended the importance of children’s education, suspended the safeguarding of children, suspended the need for medical trials and suspended all sorts of safeguards that have stood society in good stead for a long time have not changed. The conditions in Government, the media and wider society under which those decisions were made have not changed because, unfortunately, we have not yet got to the heart of the matter. Why did that pressure come from the media? Why did we have to follow what other countries were doing? Why were we obsessed with particular points of data, such as deaths from covid, rather than considering the wider impact on society? My concern about the covid inquiry is that it is asking all the wrong questions. It is concerned with who swore at whom on WhatsApp, and not the wider conditions under which decisions were made. When, several Education Secretaries ago, the former, former, former Secretary of State for Education, my right hon. Friend the Member for South Staffordshire (Sir Gavin Williamson), stood up in the House of Commons and said that he would close schools, I remember, as a mother, shouting at the television, “Don’t do it! Don’t do it!”. I could see the impact it would have—not just on my own children, but across all the wider components of society. Society is like a big machine; we cannot just take out one part and assume that the rest will continue to operate. We have seen that clearly over the past three years. We must address the reasons why these decisions were made. We cannot do that in three minutes each—we must have a longer debate. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 23 min

    Boston gain of function virus

    Please share this video, this research must STOP. Gain of function research in the USA today using enhanced potential pandemic pathogen (ePPP) research Uploaded 22-10-22 Professor Shmuel Shapira, lead scientist, Israeli Government https://www.dailymail.co.uk/health/article-11323677/Outrage-Boston-University-CREATES-Covid-strain-80-kill-rate.html This should be totally forbidden, it's playing with fire Dr Richard Ebright, Rutgers University, New Brunswick The research is a clear example of gain of function research. If we are to avoid a next lab-generated pandemic, it is imperative that oversight of enhanced potential pandemic pathogen research be strengthened. it is imperative that officials at US-government agencies, who repeatedly have placed the public at risk by repeatedly violating the existing policies be held accountable Prof David Livermore, microbiology, University of East Anglia given the strong likelihood that the Covid pandemic originated from the escape of a lab-manipulated coronavirus in Wuhan, these experiments seem profoundly unwise Boston University's National Emerging Infectious Diseases Laboratories is one of 13 biosafety level 4 labs in the US Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron 14th October 2022 Boston University School of Medicine https://www.biorxiv.org/content/10.1101/2022.10.13.512134v1 Predominant SARS-CoV-2 Omicron variant (BA.1) is highly transmissible, even in fully vaccinated individuals, and causes attenuated disease compared with other major viral variants recognized to date The Omicron spike (S) protein, unusually large number of mutations, is considered the major driver of these phenotypes We generated chimeric recombinant SARS-CoV-2 A chimera or chimeric virus One virus containing genetic material derived from two or more distinct viruses US Center for Veterinary Biologics https://www.aphis.usda.gov/animal_health/vet_biologics/publications/notice_05_23.pdf A new hybrid microorganism, created by joining nucleic acid fragments from two or more different microorganisms, in which each of at least two of the fragments, contain essential genes necessary for replication We generated chimeric recombinant SARS-CoV-2 Encoding the S gene of Omicron in the backbone of an ancestral SARS-CoV-2 isolate, and compared this virus with the naturally circulating Omicron variant. The Omicron S-bearing virus robustly escapes vaccine-induced humoral immunity, mainly due to mutations in the receptor-binding motif, yet unlike naturally occurring Omicron, efficiently replicates in cell lines and primary-like distal lung cells. In K18-hACE2 mice https://www.jax.org/strain/034860 K18-hACE2 transgenic mice express human ACE2, including airway epithelia where infections typically begin. Because K18-hACE2 are susceptible to SARS-CoV-2 and SARS-CoV viruses, they are useful for studying antiviral therapies to COVID-19 and SARS. In K18-hACE2 mice Omicron causes mild, non-fatal infection, the Omicron S-carrying virus inflicts severe disease with a mortality rate of 80%. This indicates that while the vaccine escape of Omicron is defined by mutations in S, major determinants of viral pathogenicity reside outside of S. Frankenstein, Mary Shelley, 1818 Frightful must it be; for supremely frightful would be the effect of any human endeavour to mock the stupendous mechanism of the Creator of the world (1831 edition) Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 17 min

    Vaccines and cancer

    Learn more about your ad choices. Visit megaphone.fm/adchoices Uploaded 28-03-25 Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 36 min

    Therapeutic cannabis with Professor Brighthope

    Ian Brighthope's Substack https://ianbrighthope.substack.com/ Uploaded 09-04-25 acnem provides post-graduate education to medical and allied healthcare professionals on Integrative Medicine. https://www.acnem.org/ Aligned Council of Australia https://alignedcouncilofaustralia.com.au/ World of Wellness International https://wowintl.org/ Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 2 min

    64 years

    @Campbellteaching Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 1 hr 31 min

    Dr Clare Craig, Part 3

    This excellent scientific analysis of recent events continues in interview three of this series. Follow Dr. Craig on SubStack, https://drclarecraig.substack.com COVID, the untold story. So much more makes sense after this book and my first illuminating discussion with Dr. Craig. Get your copy in the UK here: https://www.amazon.co.uk/Expired-untold-Dr-Clare-Craig/dp/1739344707 Uploaded 24-12-23 For friends in the US get your copy here, https://www.amazon.com/Expired-untold-Dr-Clare-Craig/dp/1739344707 00:00:00 - Intro 00:00:00 - asymptomatic spread, pandemic, book 00:05:43 - PCR testing, asymptomatic respiratory disease, immune system 00:11:11 - asymptomatic spread, testing, papers 00:16:40 - virus spread, presymptomatic transmission, Chinese businesswoman 00:22:16 - lockdown effectiveness, spread of respiratory viruses, slowing transmission 00:27:45 - Topics: Absurdity of people in power, Canute and his lesson, Sweden's approach to 00:33:12 - Topics: herd immunity, reducing contact, viral waves 00:38:24 - child development, isolation, hospital visits 00:43:49 - Topics: Trust in information, feedback loop, silence of friends 00:49:28 - masks, communication, dissatisfaction 00:54:39 - lockdown rules, dancing arrests, flagellants 01:00:03 - social skills, nudge unit, behavioral science 01:05:27 - tribe formation, disagreement, smaller units 01:11:00 - Variolation, smallpox vaccine, cowpox 01:16:36 - Geographical phenomenon, human behavior, immune system Have you ever felt the covid story did not entirely add up? Expired contains multiple eye-opening revelations about covid with compelling evidence that provides a coherent, sober and clear explanation that better fits the data we have so far. Meticulous research by pathologist Dr Clare Craig sheds light on the largely overlooked evidence of airborne virus transmission, examining twelve related beliefs on spread, lockdowns, asymptomatic infections, and masks. In addition, Expired champions the importance of Western ethical principles, damaged by pandemic actions and calls for their restoration. The covid debate has proved incredibly polarising. One side believed every intervention was saving lives, while the other emphasised the harms caused. Biased modelling based on a worst-case scenario led to fearful assumptions presented as fact. By dint of sheer repetition these ‘facts’ became unquestionable. Those scientists who dared to question were proclaimed dangerous. Welcome to Cloud-Covid-Land. Let’s bring back nuance. It’s time to return to reality." Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 24 min

    Expensive vaccinations for the young

    Prices, Pfizer and Moderna raise price of vaccines Uploaded 04-08-21 https://www.telegraph.co.uk/global-health/science-and-disease/coronavirus-news-nhs-double-covid-vaccine-uk-cases-isolation/ European Union supply contracts One Pfizer shot now 19.50 euros (£16.65) Up from 15.50 euros previously One Moderna dose £18.30 Up from about £16 in the first procurement deal Joint Committee on Vaccination and Immunisation https://www.gov.uk/government/news/statement-on-offering-covid-19-vaccination-to-young-people https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years https://www.bbc.co.uk/news/uk-58091693 16 and 17-year-olds in the UK will be offered a first dose soon 1.4 million will be eligible Prof Jonathan Van-Tam We have the supply and I'm expecting this to start in a very short number of weeks indeed There is no time to waste in getting on with this I want us to proceed as fast as is practically possible Pfizer-BioNTech only Routinely vaccinating children over 12 United States since May France Italy, Brazil, Japan, Israel, Hong Kong Vaccine safety https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-4-august-2021 The Pfizer-BioNTech BNT162b2 vaccine is administered via intramuscular injection, usually in the upper arm. Most frequent reactions aged 12 to 17 years Injection site pain, fever and headache Generally mild, self-limiting and short-lived, (1 to 2 days) FDA data on pericarditis and myocarditis https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-june-25-2021 Onset of symptoms within a few days after vaccination Particularly following the second dose Chest pain, shortness of breath, or feelings of having a fast-beating, fluttering, or pounding heart Pfizer-BioNTech BNT162b2 and Moderna mRNA- 1273 https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions These extremely rare adverse reactions have been more frequent shortly after the second dose, and in younger individuals and males 60 cases per million https://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm 6 or 7 times more common after the second dose 1 in 16,666 1.4 million will be eligible = 84 cases The mechanism of action underlying these rare events is not currently known Israel and the United States have reported most of the cases Milder phenotype Vast majority recovering swiftly from the acute episode, compared to more typical cases of myocarditis Benefits of vaccination Secondary school-aged children in England (early July) Antibody positive is approximately 40% England, February 2020 and March 2021 61 deaths after testing positive https://www.medrxiv.org/content/10.1101/2021.07.07.21259779v1 22 from acute infection and three from PIMS mortality rate of 2/million for the 12,023,568 CYP living in England Survival rate after testing positive = 99·995% Second wave, hospitalisation rate, 100 to 400 per million Severe neuro-disabilities, Down’s Syndrome, underlying conditions resulting in immunosuppression, severe learning disabilities March 2020 TO July 2020 449 cases of PIMS in persons under 16 years 44% were admitted to paediatric intensive care Overall case fatality ratio was 1.1% Existing studies suggest that longer term (more than 8 weeks) symptoms following SARS-CoV2 infection occur in about 1% to 10% of persons after COVID-19 Avoiding school and class-based measures Benefits to adult is highly uncertain UK, cases up a bit today https://coronavirus.data.gov.uk Includes lateral flow tests https://ourworldindata.org/coronavirus Tuesday, 4th August, + 29,312 Monday 3rd August, 21,691 L Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 20 min

    Giving injections wrongly

    Basically, we need to change the vaccine administration guidelines to include precautionary aspiration, prior to pushing in the vaccine. This will prevent cases of inadvertent intravascular administration of vaccine. Uploaded 05-11-21 Here is some discussion to suggest inadvertent intravascular vaccine administration is a variable in the aetiology of complications after adenoviral vector vaccine administration and after mRNA vaccines. These adverse events, although rare have reduced public confidence in covid vaccination, especially amongst the young, where vaccine rates are lowest. It has long been known that intravenous injection of adenovirus leads to TTS in mice https://ashpublications.org/blood/article/109/7/2832/125650/Adenovirus-induced-thrombocytopenia-the-role-of Now, new covid vaccine specific work agrees with this previous work Thrombocytopenia and splenic platelet directed immune responses after intravenous ChAdOx1 nCov-19 administration (29th June 2021) https://www.biorxiv.org/content/10.1101/2021.06.29.450356v1 The authors conclude, ‘Our work contributes to the understanding of TTS and highlights accidental intravenous injection as potential mechanism for post-vaccination TTS.’ ‘We show that intravenous but not intramuscular injection of ChAdOx1 triggers platelet-adenovirus aggregate formation and platelet activation.’ ‘Hence, safe intramuscular injection, with aspiration prior to injection, could be a potential preventive measure when administering adenovirus-based vaccines.’ Also after giving mRNA vaccines A new study finds that giving mice intravenous mRNA vaccine also causes heart inflammation in mice. Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model (August 2021) https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab707/6353927 ‘Our study indicates that IV injection of vaccines might partially contribute to this clinical phenotype, thus warranting a reconsideration of the practice of IM injection without aspiration, which carries the risk of inadvertent IV injection.’ Agreement from ‘fact check’ from Leo Nicolai, Cardiology Fellow, Ludwig Maximilian University of Munich: (German Centre for Cardiovascular Research) https://healthfeedback.org/claimreview/incorrect-vaccine-administration-is-a-potential-cause-of-post-vaccine-adverse-effects-but-more-research-is-still-needed-to-confirm-or-reject-this-hypothesis/?fbclid=IwAR0nBbM6v0V2WPFn4LxIdfR4FNAvIzLGKhzFPdQPG8mu_FR1InB8OzYQgMc ‘Indeed, there is peer-reviewed work showing in mice that possibly intravenous injection of mRNA vaccine leads to myocardial inflammation.’ ‘that intravenous injection of adenoviral vector based vaccine (AZ1222, ChAdOx1) leads to thrombocytopenia and platelet-directed immune responses, offering a possible explanation for vaccine-induced thrombosis/thrombocytopenia’ ‘these data might indicate a simple measure to lower the incidence of vaccine-induced side effects,’ ‘There is a lack of data on frequency and effects of IV injection in humans.’ Denmark has changed their national guidelines https://en.ssi.dk/news/epi-news/2021/no-19-21---2021 Based on a precautionary principle, we recommend aspiration before injection. https://www.youtube.com/watch?v=H7inaTiDKaU Evidence from Dr. Peter Gaillard (microparticulate pharmacologist) https://www.linkedin.com/pulse/astrazeneca-vaccine-pull-back-push-through-pieter-j-gaillard/?trk=pulse-article_more-articles_related-content-card Case study evidence Metallic taste in the mouth seconds after ‘intramuscular’ mRNA vaccine administration, (in the absence of an allergic reaction) https://www.youtube.com/watch?v=hbjuWs99CrE Other video-based discussions 26th September 2021 https://www.youtube.com/watch?v=nBaIRm4610o 30th September 2021 https://www.youtube.com/watch?v=KgVsd6qoyU4 Lear Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 29 min

    Omicron rise in Norway

    Link to free download of my 2 textbooks http://159.69.48.3/ Louise Restaurant and Bar, night of 26th November https://www.telegraph.co.uk/world-news/2021/12/07/europes-biggest-omicron-outbreak-appears-mild-say-norway-covid/ Oslo, Norway, Christmas party Scatec solar power company One or two returned traveller Had returned days earlier 120 people (all double vaccinated) Mingled with outside groups later 70 of the 120 plus 50 others tested positive Half tested positive for omicron 13 proven in sequencing Dr. Tine Ravlo, Oslo, infectious diseases They have symptoms like fever, cough, headache, muscle pain, fatigue, but for now none of them have become severely ill and none of them have been treated in hospital The next day, one of two employees, recently returned from South Africa tested positive Norway's state epidemiologist, Frode Forland Sheer number of people infected at a single event, omicron considerably more infectious than delta Prof Forland, Norwegian Institute of Public Health One of three scenarios for omicron, it would be both very mild and very transmissible That is the hope That is the best scenario we can have That it's getting minder, most people will get it, and they will get a natural immunity It might be that it has now replicated and mutated so many times, that this is the optimal position from the virus' point of view, to spread widely and not kill the hosts That's what we've seen with other diseases beforehand. And of course, then it gets into more like an endemic phase Now this is not the end Nor is it the end of the beginning Rather it is the beginning of the end Sally I've had Delta, this time last year (pretty rough, took 6 months to fully recover) and I have Omicron now. The symptoms of Omicron are as you state. I am vaccinated. Helgard Living in SA (Gauteng) and have tested (+) 2 days ago, The symptoms is 100% correct as stated. Also after 1st symptoms, 3 days after i don't even know that i was sick. Body and muscle aches and pains Headache Tiredness (1 to 2 days) Slight sore throat No severe cough No runny nose Graph refs https://ourworldindata.org/coronavirus SA. Live data, hospital patients who have tested positive https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/daily-hospital-surveillance-datcov-report/ South Africa references https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/sars-cov-2-genomic-surveillance-update/ Weekly deaths in SA https://www.samrc.ac.za/reports/report-weekly-deaths-south-africa Variants in SA https://www.worldometers.info/coronavirus/country/south-africa/ Sir Patrick Vallance from pandemic to endemic where this becomes a more regular infection like flu over time This virus has mutated a lot, quickly and that is sort of what you would expect at this stage the good news is that, so far, it looks as though when you get very high antibody levels with the booster vaccine it's definitely having some effect against it in the laboratory studies Boris Johnson Work-from-home from Monday Facemasks will be enforced in public venues Covid passes mandatory for nightclubs Daily testing instead of isolation for omicron contacts First plant-based coronavirus vaccine CoVLP (20 years of R and D) https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-positive-phase-3-efficacy-and-safety-results/ GlaxoSmithKline and Medicago Primary endpoints and secondary endpoints met in trial dominated by COVID-19 variants Efficacy demonstrated against all variants seen in the study, including 75.3% efficacy against COVID-19 of any severity caused by Delta variant Vaccine candidate was well-tolerated, with no related serious adverse events reported in the vaccine group 24,000 adults across six countries Phase 3 placebo-controlled efficacy study Canada Medicago’s p Learn more about your ad choices. Visit megaphone.fm/adchoices

  • October 10 · 17 min

    New ignored TB treatment

    Professor of Oncology, Angus Dalgleish gives vital information on a repurposed drug he uses for his cancer patients, given at a very low dose. This is Low Dose Naltrexone. Uploaded 13-06-25 Check out the LDN trust website for much more, https://ldnresearchtrust.org Naltrexone at low doses (LDN) and its relevance to cancer therapy https://openaccess.sgul.ac.uk/id/eprint/114135/ Naltrexone was designed to inhibit opioid receptors without activating them and hence used to block the stimulatory effects of morphine and heroin. It was noted that in certain patients being treated with naltrexone for an opioid addiction many reported significant secondary benefit when being weaned off naltrexone. This group of patients had chronic inflammatory and autoimmune conditions and reported improvements whilst using the lower dosages of naltrexone. There have also been recent anecdotal reports of cancer resolution following the use of low doses of naltrexone (LDN). However, the mechanism of action is unclear. Areas covered We review three mechanisms through which LDN can influence cancer progression; namely, (a) antagonism of receptors to which LDN binds, which include toll-like receptors 7–9 that lead to IL-6 suppression b) modulation of immune function in patients; and c) direct inhibition of signaling pathways involved in cancer cell control, including the priming of pro-apoptotic pathways. Expert opinion Considering the increase in the number of anecdotal reports of activity, there will likely be a bigger drive toward using LDN in the oncological setting. These reports support clinical trials of LDN in cancer, especially when given in combination with certain chemotherapy. https://ldnresearchtrust.org/angus-dalgleish-md-role-ldn-management-cancer-2018-conference-ldn-low-dose-naltrexone Major clinical evidence on the use of low-dose naltrexone in the treatment of cancer: a systematic review https://www.researchgate.net/publication/384236060_Major_clinical_evidence_on_the_use_of_low-dose_naltrexone_in_the_treatment_of_cancer_a_systematic_review https://www.tandfonline.com/doi/full/10.1080/14737140.2022.2037426#abstract Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Showing 541–560 of 772 episodes